Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dose-response Relationship Study of S42909 on Leg Ulcer Healing
NCT03077165 · View on ClinicalTrials.gov ↗
Study Summary
Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
Conditions Studied
Interventions
- DRUG S42909 100 mg
- DRUG S42909 200 mg
- DRUG S42909 400 mg
- DRUG S42909 800 mg
- DRUG S42909 1200 mg
Study Locations (20)
California
- ILD Research Center — Carlsbad
- Center for Clinical Research Inc. — Carmichael
- Center for Clinical Research Inc. — Castro Valley
- Limb Preservation Platform, Inc. — Fresno
- Foot and Ankle Clinic — Los Angeles
- Stanford Hospitals and Clinics — Redwood City
- Center for Clinical Research Inc. — San Francisco
Other
- Centro Dr Bottini de flebologia y estetica — Ciudad Autonoma de Buenos Aire
- Hospital Italiano de La Plata — La Plata
- DIM Clinica Privada — Ramos Mejía
- Sanatorio Mapaci — Rosario
- Medizinische Universitaet Innsbruck Universitaetsklinik für Gefässchirurgie — Innsbruck
- VENEX Zentrum fuer minimal invasive Venentherapie — Vienna
Pennsylvania
- The Snyder Institute for Vascular Health and Research — Kittanning
- D&P Medical Group, LLC — Pittsburgh
- Serena Group Research Foundation — Pittsburgh
Florida
- University of Miami Hospital Wound Center — Miami
Idaho
- St. Luke's Intermountain Research Center — Boise
Illinois
- Podiatry 1st — Belleville
Nevada
- Advanced Foot & Ankle Center — Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077165
The ClinicalTrials.gov registry entry for NCT03077165 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ilkos Therapeutic, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 5 interventions — of which S42909 100 mg is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03077165 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Other, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03077165 about?
NCT03077165 is a clinical study titled "Dose-response Relationship Study of S42909 on Leg Ulcer Healing". Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer.
What is the current status of trial NCT03077165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2017-09-12. Estimated completion is 2020-01-22.
What conditions does trial NCT03077165 study?
This clinical trial studies the following conditions: Venous Leg Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03077165?
The interventions under investigation include: S42909 100 mg (DRUG), S42909 200 mg (DRUG), S42909 400 mg (DRUG), S42909 800 mg (DRUG), S42909 1200 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03077165?
This trial is sponsored by Ilkos Therapeutic, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03077165 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.